Digital process design to define and deliver pharmaceutical particle attributes
Urwin, Stephanie J. and Chong, Magdalene W.S. and Li, Wei and McGinty, John and Mehta, Bhavik and Ottoboni, Sara and Pathan, Momina and Prasad, Elke and Robertson, Murray and McGowan, Mark and al-Attili, Mais and Gramadnikova, Ekaterina and Siddique, Mariam and Houson, Ian and Feilden, Helen and Benyahia, Brahim and Brown, Cameron J. and Halbert, Gavin W. and Johnston, Blair and Nordon, Alison and Price, Chris J. and Reilly, Chris D. and Sefcik, Jan and Florence, Alastair J. (2023) Digital process design to define and deliver pharmaceutical particle attributes. Chemical Engineering Research and Design, 196. pp. 726-749. ISSN 0263-8762 (https://doi.org/10.1016/j.cherd.2023.07.003)
Preview |
Text.
Filename: Urwin_etal_CERD_2023_Digital_process_design_to_define_and_deliver_pharmaceutical_particle_attributes.pdf
Final Published Version License: Download (5MB)| Preview |
Abstract
A digital-first approach to produce quality particles of an active pharmaceutical ingredient across crystallisation, washing and drying is presented, minimising material requirements and experimental burden during development. To demonstrate current predictive modelling capabilities, the production of two particle sizes (D 90 = 42 and 120 µm) via crystallisation was targeted to deliver a predicted, measurable difference in in vitro dissolution performance. A parameterised population balance model considering primary nucleation, secondary nucleation and crystal growth was used to select the modes of production for the different particle size batches. Solubility prediction aided solvent selection steps which also considered manufacturability and safety selection criteria. A wet milling model was parameterised and used to successfully produce a 90 g product batch with a particle size D 90 of 49.3 µm, which was then used as the seeds for cooling crystallisation. A rigorous approach to minimising physical phenomena observed experimentally was implemented, and successfully predicted the required conditions to produce material satisfying the particle size design objective of D 90 of 120 µm in a seeded cooling crystallisation using a 5-stage MSMPR cascade. Product material was isolated using the filtration and washing processes designed, producing 71.2 g of agglomerated product with a primary particle D 90 of 128 µm. Based on experimental observations, the population balance model was reparametrised to increase accuracy by inclusion of an agglomeration term for the continuous cooling crystallisation. The dissolution performance for the two crystallised products is also demonstrated, and after 45 min 104.0 mg of the D 90 of 49.3 µm material had dissolved, compared with 90.5 mg of the agglomerated material with D 90 of 128 µm. Overall, 1513 g of the model compound was used to develop and demonstrate two laboratory scale manufacturing processes with specific particle size targets. This work highlights the challenges associated with a digital-first approach and limitations in current first-principles models are discussed that include dealing ab initio with encrustation, fouling or factors that affect dissolution other than particle size.
ORCID iDs
Urwin, Stephanie J. ORCID: https://orcid.org/0000-0002-9092-0200, Chong, Magdalene W.S., Li, Wei, McGinty, John ORCID: https://orcid.org/0000-0002-8166-7266, Mehta, Bhavik, Ottoboni, Sara ORCID: https://orcid.org/0000-0002-2792-3011, Pathan, Momina, Prasad, Elke ORCID: https://orcid.org/0000-0002-5412-9374, Robertson, Murray ORCID: https://orcid.org/0000-0001-9543-7667, McGowan, Mark, al-Attili, Mais ORCID: https://orcid.org/0000-0002-1192-5020, Gramadnikova, Ekaterina, Siddique, Mariam ORCID: https://orcid.org/0000-0002-3054-7192, Houson, Ian, Feilden, Helen, Benyahia, Brahim, Brown, Cameron J. ORCID: https://orcid.org/0000-0001-7091-1721, Halbert, Gavin W., Johnston, Blair ORCID: https://orcid.org/0000-0001-9785-6822, Nordon, Alison ORCID: https://orcid.org/0000-0001-6553-8993, Price, Chris J. ORCID: https://orcid.org/0000-0002-0790-6003, Reilly, Chris D., Sefcik, Jan ORCID: https://orcid.org/0000-0002-7181-5122 and Florence, Alastair J. ORCID: https://orcid.org/0000-0002-9706-8364;-
-
Item type: Article ID code: 86087 Dates: DateEvent31 August 2023Published6 July 2023Published Online3 July 2023AcceptedSubjects: Technology > Chemical engineering
Medicine > Pharmacy and materia medica > Pharmaceutical technologyDepartment: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Faculty of Science > Pure and Applied Chemistry
Faculty of Engineering > Chemical and Process Engineering
Technology and Innovation Centre > Continuous Manufacturing and Crystallisation (CMAC)
Strategic Research Themes > Measurement Science and Enabling Technologies
Strategic Research Themes > Advanced Manufacturing and Materials
Technology and Innovation Centre > BionanotechnologyDepositing user: Pure Administrator Date deposited: 10 Jul 2023 13:41 Last modified: 14 Oct 2024 00:43 URI: https://strathprints.strath.ac.uk/id/eprint/86087